Drug intelligence / Profile preview

YHC2124

Development stage: Preclinical
Lead developer: Yuhan
Administration: Subcutaneous

Overview

YHC2124 is a preclinical-stage oncology drug candidate under development by Yuhan Corporation. It is currently being investigated for the treatment of various solid tumors. As part of Yuhan's early-stage 'YHC' pipeline series, specific details regarding its molecular target, mechanism of action, and modality (such as whether it is a small molecule or a biologic) have not yet been publicly disclosed. The asset represents Yuhan's strategic expansion of its oncology portfolio, following the success of more advanced programs like lazertinib.

Beyond the preview

Go deeper on YHC2124.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YHC2124.

Explore the full profile